1,721,367 research outputs found
[Interactions between drugs, environment and health: a new challenge for epidemiology.]
No full text: Traditionally, the effects of drugs and of environmental factors on health have been studied independently. Recently, several research groups have started to broaden the view and consider potential overlaps and interactions between environmental exposures and drug use. In Italy, regardless the strong competencies in environmental and pharmaco-epidemiology and the availability of detailed data, to date research in the fields of pharmacoepidemiology and environmental epidemiology is mainly being conducted in silos, but time has come to dedicate attention to possible convergence and integration between the two disciplines. The present contribution aims at introducing the topic and highlighting potential for opportunities in research by illustrating some examples
Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
No full text
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
No full text
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
No full textAIM:
The aim of this article is to investigate the vascular safety profile of triptans through an analysis of the United States Food and Drug Administration Adverse Event Reporting System (FDA_AERS) database with a special focus on serious and unexpected adverse events.
METHODS:
A CASE/NON-CASE analysis was performed on the reports entered in the FDA_AERS from 2004 to 2010: CASES were reports with at least one event included in the MedDRA system organ classes 'Cardiac disorder' or 'Vascular disorders', whereas NON-CASES were all the remaining reports. Co-reported cardiovascular drugs were used as a proxy of cardiovascular risk and the adjusted reporting odds ratio (adj.ROR) with 95% confidence intervals (95% CI) was calculated. Disproportionality signals were defined as adj.ROR value >1. Adverse events were considered unexpected if not mentioned on the relevant label.
RESULTS:
Among 2,131,688 reports, 7808 concerned triptans. CASES were 2593 among triptans and 665,940 for all other drugs. Unexpected disproportionality signals were found in the following high-level terms of the MedDRA hierarchy: 'Cerebrovascular and spinal necrosis and vascular insufficiency' (103 triptan cases), 'Aneurysms and dissections non-site specific' (15), 'Pregnancy-associated hypertension' (10), 'Reproductive system necrosis and vascular insufficiency' (3).
DISCUSSION:
Our analysis revealed three main groups of unexpected associations between triptans and serious vascular events: ischaemic cerebrovascular events, aneurysms and artery dissections, and pregnancy-related vascular events. A case-by-case assessment is needed to confirm or disprove their plausibility and large-scale analytical studies should be planned for risk rate estimation. In the meantime, clinicians should pay special attention to migraine diagnosis and vascular risk assessment before prescribing a triptan, also promptly reporting any unexpected event to pharmacovigilance systems
Safety Meta-Analysis A Call for Appropriate Use of Disproportionality Measures from Spontaneous Reporting Systems
No full text
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice
No full text- …
